Oral tofacitinib (Xeljanz), a JAK inhibitor, helped regrow hair in three quarters of pediatric patients with alopecia areata (AA) in a small study conducted at the University of Colorado and ...

Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment ...

Treatment with Xeljanz in adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients, with mild adverse events, according to recently published study ...

Alopecia areata, the second most common form of hair loss, ... "Together, the two studies show that we're on the right track," said Dr. Christiano, who is a co-author of the tofacitinib paper.

In a recent retrospective study of 90 adults with severe alopecia areata (at least 40% scalp hair loss) who were treated for 4 to 18 months with tofacitinib, 20% had nearly total hair regrowth, 58 ...

Huang J, Deng S, Li J, et al. Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study. Acta Derm Venereol . 2023;103:adv13475. doi:10.2340/actadv ...

The initial success of tofacitinib for alopecia areata patients generated a lot of excitement, so it's not uncommon for some dermatologists to prescribe tofacitinib off-label to alopecia patients ...

It occurs when a faulty immune system attacks healthy hair follicles. Alopecia universalis is a severe form of alopecia ...

The FDA has approved Olumiant, the first systemic medication for the treatment of alopecia areata, according to a press release. Olumiant (baricitinib, Eli Lilly/Incyte) is a once-daily oral Janus ...

While there have been case reports of topical JAK inhibitors for alopecia areata, larger clinical trials of ruxolitinib 1.5% cream and delgocitinib ointment and tofacitinib 2% ointment have not ...

Images showing the alopecia patient during treatment with tofacitinib to regrow his hair. 1st panel- before treatment. 2nd panel- 2 months into treatment. 3rd panel- 5 months into treatment. 4th ...

Alopecia Areata is Driven by Cytotoxic T Lymphocytes and is Reversed by JAK Inhibition, Raphael Clynes, Angela M. Christiano et al., published in Nature Medicine, 17 August 2014.DOI:10.1038/nm ...